Multiple sclerosis and related disordersHumansRituximabOff-Label UseMultiple SclerosisImmunologic Factors
Recommendations for the use of off-label rituximab for the treatment of multiple sclerosis in low-resource settings.
Nick Rijke, Bassem I Yamout, Deanna Saylor, Francesco Nonino, Graziella Filippini, Thomas Piggott, Joanna Laurson-Doube, Laura Amato, Tapas K Banerjee, Kathleen Costello, Cinzia Del Giovane, Nicola De Stefano, Najoua El Abkari, Gavin Giovannoni, Hans-Peter Hartung
Published: 202610.1016/j.msard.2025.106878
Abstract
BACKGROUND: Rituximab is a commonly used off-label disease-modifying treatment (DMT) for multiple sclerosis (MS). The MS International Federation (MSIF) articulated the need for evidence-based recommendations on the use of the medicine in 2021, with…
Preview only. Read the full abstract at the source